82 related articles for article (PubMed ID: 24239883)
1. Inhibition of PARP1 by small interfering RNA enhances docetaxel activity against human prostate cancer PC3 cells.
Wu W; Kong Z; Duan X; Zhu H; Li S; Zeng S; Liang Y; Iliakis G; Gui Z; Yang D
Biochem Biophys Res Commun; 2013 Dec; 442(1-2):127-32. PubMed ID: 24239883
[TBL] [Abstract][Full Text] [Related]
2. PARP1-siRNA suppresses human prostate cancer cell growth and progression.
Lai Y; Kong Z; Zeng T; Xu S; Duan X; Li S; Cai C; Zhao Z; Wu W
Oncol Rep; 2018 Apr; 39(4):1901-1909. PubMed ID: 29393407
[TBL] [Abstract][Full Text] [Related]
3. Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications.
Park SH; Jang KY; Kim MJ; Yoon S; Jo Y; Kwon SM; Kim KM; Kwon KS; Kim CY; Woo HG
Oncotarget; 2015 Dec; 6(42):44819-31. PubMed ID: 26540566
[TBL] [Abstract][Full Text] [Related]
4. EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).
Hour TC; Chung SD; Kang WY; Lin YC; Chuang SJ; Huang AM; Wu WJ; Huang SP; Huang CY; Pu YS
Arch Toxicol; 2015 Apr; 89(4):591-605. PubMed ID: 24888374
[TBL] [Abstract][Full Text] [Related]
5. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 4 ligation confers chemoresistance to docetaxel on PC-3 human prostate cancer cells.
Zhang Y; Wang Y; Yuan J; Qin W; Liu F; Wang F; Zhang G; Yang X
Cell Biol Toxicol; 2012 Aug; 28(4):269-77. PubMed ID: 22648782
[TBL] [Abstract][Full Text] [Related]
7. MHY-449, a novel dihydrobenzofuro[4,5-b][1,8] naphthyridin-6-one derivative, induces apoptotic cell death through modulation of Akt/FoxO1 and ERK signaling in PC3 human prostate cancer cells.
Lee SH; Kang YJ; Sung B; Kim DH; Lim HS; Kim HR; Kim SJ; Yoon JH; Moon HR; Chung HY; Kim ND
Int J Oncol; 2014 Mar; 44(3):905-11. PubMed ID: 24424889
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.
Brenner JC; Ateeq B; Li Y; Yocum AK; Cao Q; Asangani IA; Patel S; Wang X; Liang H; Yu J; Palanisamy N; Siddiqui J; Yan W; Cao X; Mehra R; Sabolch A; Basrur V; Lonigro RJ; Yang J; Tomlins SA; Maher CA; Elenitoba-Johnson KS; Hussain M; Navone NM; Pienta KJ; Varambally S; Feng FY; Chinnaiyan AM
Cancer Cell; 2011 May; 19(5):664-78. PubMed ID: 21575865
[TBL] [Abstract][Full Text] [Related]
9. Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.
Han S; Brenner JC; Sabolch A; Jackson W; Speers C; Wilder-Romans K; Knudsen KE; Lawrence TS; Chinnaiyan AM; Feng FY
Neoplasia; 2013 Oct; 15(10):1207-17. PubMed ID: 24204199
[TBL] [Abstract][Full Text] [Related]
10. Polymerase independent repression of FoxO1 transcription by sequence-specific PARP1 binding to FoxO1 promoter.
Tian YN; Chen HD; Tian CQ; Wang YQ; Miao ZH
Cell Death Dis; 2020 Jan; 11(1):71. PubMed ID: 31992690
[TBL] [Abstract][Full Text] [Related]
11. PARP1 inhibitors attenuate AKT phosphorylation via the upregulation of PHLPP1.
Wang S; Wang H; Davis BC; Liang J; Cui R; Chen SJ; Xu ZX
Biochem Biophys Res Commun; 2011 Aug; 412(2):379-84. PubMed ID: 21821012
[TBL] [Abstract][Full Text] [Related]
12. The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity.
Zhai L; Li S; Li X; Li H; Gu F; Guo X; Liu F; Zhang X; Fu L
Pathol Res Pract; 2015 Feb; 211(2):130-7. PubMed ID: 25480692
[TBL] [Abstract][Full Text] [Related]
13. Effect and mechanism of poly (ADP-ribose) polymerase-1 in aldosterone-induced apoptosis.
Qiao W; Zhang W; Shao S; Gai Y; Zhang M
Mol Med Rep; 2015 Aug; 12(2):1631-8. PubMed ID: 25872931
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
Zhang HR; Chen JM; Zeng ZY; Que WZ
J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
[TBL] [Abstract][Full Text] [Related]
15. Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity.
Kim J; Long KE; Tang K; Padanilam BJ
Kidney Int; 2012 Jul; 82(2):193-203. PubMed ID: 22437413
[TBL] [Abstract][Full Text] [Related]
16. PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol.
Szanto A; Hellebrand EE; Bognar Z; Tucsek Z; Szabo A; Gallyas F; Sumegi B; Varbiro G
Biochem Pharmacol; 2009 Apr; 77(8):1348-57. PubMed ID: 19426673
[TBL] [Abstract][Full Text] [Related]
17. Curcumin induces apoptosis in pancreatic cancer cells through the induction of forkhead box O1 and inhibition of the PI3K/Akt pathway.
Zhao Z; Li C; Xi H; Gao Y; Xu D
Mol Med Rep; 2015 Oct; 12(4):5415-22. PubMed ID: 26166196
[TBL] [Abstract][Full Text] [Related]
18. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.
Gan Y; Shi C; Inge L; Hibner M; Balducci J; Huang Y
Oncogene; 2010 Sep; 29(35):4947-58. PubMed ID: 20562913
[TBL] [Abstract][Full Text] [Related]
19. Regulation of FOXO1-mediated transcription and cell proliferation by PARP-1.
Sakamaki J; Daitoku H; Yoshimochi K; Miwa M; Fukamizu A
Biochem Biophys Res Commun; 2009 May; 382(3):497-502. PubMed ID: 19281796
[TBL] [Abstract][Full Text] [Related]
20. c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance.
Pyndiah S; Tanida S; Ahmed KM; Cassimere EK; Choe C; Sakamuro D
Sci Signal; 2011 Mar; 4(166):ra19. PubMed ID: 21447800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
